Rimegepant is a safe and efficacious pharmacological treatment of acute migraine in adults.
Results from the ACHIEVE II study were presented at the American Headache Society's 60th Annual Scientific Meeting.
The use of transnasal sphenopalatine ganglion block is safe and effective for providing short-term relief from acute migraine headaches.
The FDA has posted a discontinuation notice for Zecuity, an iontophoretic transdermal system for the treatment for acute migraine in adults.
In a phase 3 trial, treatment with erenumab reduced migraine frequency, monthly migraine days, and migraine medication use in patients with episodic migraine.
Pregnant women who seek treatment for acute migraine may experience higher rates of preterm delivery, preeclampsia, and low birth weight compared with the general population.
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis